We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

ETHICON J & J Surgical Technologies

Ethicon, a Johnson & Johnson MedTech company, collaborates with clinicians and health care experts around the world t... read more Featured Products: More products

Download Mobile App

Biologic Sealant Patch Delivers Hemostatic Efficacy

By HospiMedica International staff writers
Posted on 12 Apr 2015
Print article
The EVARREST Fibrin Sealant Patch
The EVARREST Fibrin Sealant Patch (Photo courtesy of ETHICON J & J Surgical Technologies)
An innovative fibrin sealant patch offers a solution for controlling problematic bleeding situations, including adult liver surgery.

The EVARREST Fibrin Sealant Patch is a novel, bioabsorbable hemostat which contains embedded biologics—human thrombin and fibrinogen—that promote rapid and durable clot formation by augmenting the human coagulation system. The technology is comprised of a 10.2 × 10.2 cm flexible composite patch that incorporates the embedded thrombin and fibrinogen, a backing of Polyglactin 910 non-woven fibers, and an oxidized regenerated cellulose (ORC) padding layer.

The patch is positioned with manual compression for three minutes as an adjunct to hemostasis of soft tissue bleeding during open retroperitoneal, intra-abdominal, pelvic, and non-cardiac thoracic surgery, when control of bleeding by standard surgical methods of hemostasis, such as sutures, ligature, and cautery are ineffective or impractical. Studies have demonstrated that the EVARREST is greater than 94% effective in controlling bleeding across challenging patient types and surgical situations, compared to current standard of care (less than 53%).

The Ethicon EVARREST Fibrin Sealant Patch is a product of Ethicon (Somerville, NJ, USA), and current approval for use by the US Food and Drug Administration (FDA) has been expanded for use in adult liver surgery.

“We see EVARREST as a game changer - better equipping surgeons to handle bleeding, thereby potentially improving patient outcomes, reducing OR costs and providing peace of mind for the entire surgical staff,” said Dan Wildman, vice president of global franchise strategy and innovation for Ethicon.

“The liver is a particularly hard-to-control bleed site during surgery, as blood loss is often higher and hemostasis may be difficult to achieve,” said Krishna Athota, MD, a trauma and critical care surgeon at the University of Cincinnati (OH, USA). “This expanded indication for EVARREST reinforces this innovation's potential to make problematic bleeding situations routine, and could result in a paradigm shift in the treatment of bleeding during surgery.”

Related Links:


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
Harness System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
Click here to Register


Critical Care

view channel
Image: This study is significant as it addresses a treatment approach that has not been extensively studied before (Photo courtesy of 123RF)

Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease

There has been a lack of extensive research on the use of drug-coated balloon (DCB)-only strategy for the treatment of de novo left main coronary artery disease, especially in high bleeding risk (HBR) patients.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.